Asco 2022 – great expectations for Adicet, Arcellx and PMV
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
No regrets as Lyell prepares for its first clinical trial
The preclinical company pulled off a giant flotation, and though its stock has since slumped it now has several years’ cash to play with.
Esmo 2021 – Mirati bids to be belle of the ball
At a conference largely focused on big biopharma a few biotech catalysts stand out.
Roche U-turns and Adaptimmune wins
A low-key cancer discovery alliance sees Roche abandoning its earlier opposition to cell therapies.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
